The iPortVR is a vitreoretinal oculosubarachnoid glaucoma device (VOGD), inserted via the ab-interno (from the inside) pathway. The device creates a micro shunt communication between the ocular posterior chamber and the retrolaminar subarachnoid space.
The iPortVR is the first ever glaucoma device designed for use during vitreoretinal(VR) surgery, which is commonly associated with glaucoma. iValve technology built into the design makes the iPortVR compatible for use with all VR tamponading agents.
The iPortVR offers the highly effective, cost saving benefits of oculosubarachnoid shunting, while making use of ab-interno implantation to be fast, simple and minimally invasive to insert.
Pre-clinical testing of the iPortVR is currently underway. The Glaucoma treatment by Oculosubarachnoid Vitreoretinal Implant Device (GOVID) study is the iPortVR early feasibility study planned to kick off in 2021.